Scancell Holdings Plc
("Scancell" or the "Company")
BLOCK LISTING SIX MONTHLY RETURN
Date: 16 February 2021
| Name of applicant: | Scancell Holdings plc | |||
| Name of scheme: | Convertible Loan Notes Shares
| |||
| Period of return: | From: | 12 August 2020 | To: | 15 February 2021 |
| Number of securities originally admitted at date of admission | 96,774,193 ordinary shares of £0.001 each 12 August 2020
| |||
| Balance of unallotted securities under scheme(s) from previous return: | 96,774,193 ordinary shares of £0.001 each
| |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | 69,719,566 ordinary shares of £0.001 each | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 27,054,627 ordinary shares of £0.001 each
| |||
|
|
|
|
|
|
| Name of contact: | Dr Cliff Holloway, CEO |
| Telephone number of contact: | +44 (0) 20 3727 1000 |
For Further Information:
| Scancell Holdings plc |
|
|
| Dr John Chiplin, Chairman |
| +44 (0) 20 3727 1000 |
| Dr Cliff Holloway, CEO |
|
|
|
|
|
|
| Panmure Gordon (UK) Limited |
|
|
| Freddy Crossley/Emma Earl (Corporate Finance) |
| +44 (0) 20 7886 2500 |
| Rupert Dearden (Corporate Broking) |
|
|
|
|
|
|
| FTI Consulting |
|
|
| Simon Conway/Natalie Garland-Collins |
| +44 (0) 20 3727 1000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
